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an extended hypofractionated 
Palliative radiotherapy regimen 
for head and neck carcinomas
 
Michael Laursen, Lena Specht, Claus Andrup Kristensen, Anita Gothelf,  
Mogens Bernsdorf, Ivan Vogelius and Jeppe Friborg*
Department of Oncology, National University Hospital, Rigshospitalet, Copenhagen, Denmark
Background: Palliative radiotherapy to patients with head and neck cancer is often 
necessary, but there is a substantial variation in the treatment regimens reported in the 
literature, and consensus on the most appropriate schedules does not exist. In order to 
minimize acute toxicity while at the same time trying to achieve prolonged tumor control, 
a long hypofractionated regimen has been used routinely in Denmark. In the current 
retrospective study, we investigated the outcome in patients intended for palliative radio-
therapy with this regimen.
Materials and methods: Patients with newly diagnosed head and neck cancer treated 
with palliative radiotherapy of 52–56 Gy in 13–14 fractions twice weekly from 2009 to 
2014 were included. Patients were excluded if they had previously received radiotherapy. 
Data on disease location, stage, patient performance status (PS), treatment response, 
acute skin and mucosal toxicity, and late fibrosis were collected prospectively and sup-
plemented with information from medical records.
results: 77 patients were included in the study. Fifty-eight patients (75%) completed the 
intended treatment. Loco-regional tumor response (complete or partial) was evaluated 
2 months posttreatment and observed in 45% of the entire population corresponding 
to 71% of patients alive. PS had a significant influence on survival (p = 0.007) and on 
not completing the intended treatment. Grade III or IV acute mucositis were observed in 
25%, and grade III or IV acute dermatitis observed in 15%.
conclusion: Palliative hypofractionated radiotherapy with 52–56 Gy in 13–14 fractions 
shows good tumor response and tolerability in a vulnerable patient population. However, 
it may not be suited for patients in poor PS.
Keywords: head–neck cancer, palliative treatment, radiotherapy, hypofractionation, iMrT
inTrODUcTiOn
Cancer of the head and neck is a common malignant disease. In 2012, there were 686,000 new cases, 
accounting for approximately 5% of all new cancer cases worldwide (1). This included cancers of the 
oral cavity, pharynx, and larynx, with most of them being squamous cell carcinomas. Patients with 
head and neck cancer often present with pain and dysphagia as primary symptoms, and left untreated 
the prognosis for these patients is very poor with a median survival below 4 months (2).
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Curative radiotherapy of head and neck cancer is a time-
consuming and intensive treatment, associated with significant 
morbidity, both in the acute and late setting (3). Acute morbidity 
occurs over a period of several weeks to months and includes 
severe mucositis, pain, and dysphagia, which is not tolerable for 
all patients. However, as advanced head and neck cancer is often 
associated with severe local morbidity, including ulceration, pain, 
and dysphagia, disease control and symptomatic treatment are 
still necessary. Therefore, palliative radiotherapy is a reasonable 
treatment option in patients with primary metastatic disease or 
when treatment of locally advanced disease with curative intent is 
not possible due to comorbidity or poor performance status (PS).
There is no international consensus on the schedule of palliative 
radiotherapy and many different regimens have been proposed, 
often based on local tradition and infrastructure settings.
Published regimens include the QUAD-shot consisting of 
3.5 Gy twice-daily fractions given over two consecutive days to a 
total of 14 Gy per cycle, with a 3- to 4-week break between cycles, 
with a maximum of three cycles (4–10). Other examples include 
30 Gy in 10 fractions given over 2 weeks (11–13), 48 Gy in 12 
fractions 3–4 times a week (14), 20 Gy in five fractions over five 
consecutive days (15–17), the “0–7–21” regimen (24 Gy in three 
fractions of 8 Gy each, given on days 0, 7, and 21) (18), 40 Gy in 
10 fractions, twice weekly (19), 50 Gy in 20 fractions split course 
(12), and 50 Gy in 16 fractions, five fractions/week (20).
Thus, there are significant variations in course duration and 
maximum doses delivered, and this reflects slightly different 
agendas, from the aim of obtaining swift palliation with short 
schedules (e.g., 20 Gy/5  fx or 30 Gy/10  fx) to schedules aimed 
at prolonged disease control (14, 20). The challenges associated 
with the latter schedules are the significant acute toxicity which 
approaches the severity seen in radical treatment. In order to 
find a compromise between acute toxicity and prolonged disease 
control in patients not suitable for radical treatment, but where 
prolonged disease control was desirable, a palliative radiotherapy 
schedule consisting of 52–56 Gy in 13–14 fractions, two fractions 
per week has been used in Denmark for head–neck cancer.
In this study, we retrospectively investigated the outcome in 
patients treated with this schedule between 2009 and 2014 at 
Copenhagen University Hospital Rigshospitalet, Denmark.
PaTienTs anD MeThODs
Patient selection
Patients diagnosed with primary head and neck carcinoma at 
Rigshospitalet, Denmark between 2009 and 2014 were eligible 
and included if they were planned to receive palliative radio-
therapy with 52–56 Gy/13–14 fractions, two fractions/week. We 
also included eight patients that earlier had received surgery with 
curative intent, but later received palliative radiotherapy after a 
loco-regional recurrence. Patients were excluded if they did not 
receive any fractions of palliative radiotherapy, had previously 
received radiotherapy in the head and neck region or had other 
active cancers. The decision to provide palliative radiotherapy 
instead of treatment with curative intent was based on an indi-
vidual assessment, including PS, presence of metastatic disease 
or presence of significant comorbidities (for example excessive 
alcohol abuse or heart conditions).
Data collection
Data on diagnosis, treatment, and morbidity were reported pro-
spectively in the structured DAHANCA recording sheets and 
recorded in the DAHANCA clinical database. During treatment, 
patients were evaluated weekly for symptoms and signs of radi-
ation-induced mucositis and dermatitis with predefined scores. 
Mucositis was graded as follows; no reactions (0), erythema (1), 
patchy mucositis (2), confluent mucositis (3), and ulceration (4). 
Similarly, dermatitis was graded as; no reaction (0), erythema (1), 
dry desquamation (2), moist desquamation (3), and ulceration (4).
Furthermore, patients were evaluated at 14 days and 2 months 
after completed treatment according to the DAHANCA guide-
lines. The evaluation included physical examination, inspection 
of the oral cavity, palpation of the cervical lymph nodes, and 
fiberoptic endoscopy of the pharynx and larynx. Evaluation of the 
macroscopic tumor response on the neck (primary and nodes) 
was categorized as complete response (CR), partial response (PR), 
no change (NC), progressive disease (PD), and not evaluable 
(NE), if the clinician could not evaluate the response. Imaging 
was not performed on a routine basis and is not part of the follow-
up program defined by DAHANCA for patients treated in the 
palliative setting.
Patients who were seen beyond the 2-month evaluation, were 
also evaluated for late fibrosis, although not routinely. Fibrosis 
was evaluated as; no fibrosis (0), discrete fibrosis (1), moderate 
fibrosis (2), and severe fibrosis (3).
In case of missing data the relevant patient files were examined 
to complete the data. Approvals were obtained from the Danish 
Data Protection Agency (j.nr. RH-2016-368) and the National 
Board of Health (j.nr. 3-3013-1849/1).
radiotherapy Planning
For planning purposes, the gross tumor volume (GTV) was 
delineated and the clinical target volume created by expanding 
the GTV by a concentric 1-cm margin modified to exclude air 
and intact bone. All patients were treated in a thermoplastic mask 
and an additional margin of 0.4 cm was added for the planning 
target volume. Elective nodal volumes were not included. Organs 
at risk included the spinal cord, brainstem, parotid glands, 
submandibular glands, and optic structures when relevant. The 
maximal dose to the spinal cord and brain stem were 33.9 and 
39.3 Gy (biologically equivalent to 39 and 51 Gy in 2-Gy frac-
tions using an α/β ratio of 2 and delivered over 13 fractions). All 
patients were treated with intensity-modulated radio therapy 
(IMRT).
statistical analysis
Descriptive statistics were used to summarize the patients’ charac-
teristics and Kaplan–Meier survival analysis was used to compare 
survival in different groups with the log-rank test used for signifi-
cance testing. Overall survival (OS) was calculated from date of 
first palliative radiotherapy fraction to date of death or October 
31, 2016, whichever came first. Due to the unique personal identi-
fier in Denmark and the mandatory national databases, updated 
TaBle 1 | Study Population (n = 77).
characteristics n(%)
gender
Male
Female
53 (69)
24 (31)
Primary tumor site
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Sinonasal
Salivary glands
Unknown primary tumor
16 (21)
1 (1)
23 (30)
9 (12)
14 (18)
6 (8)
4 (5)
4 (5)
histopathology
Squamous cell carcinoma
Other types
72 (94)
5 (6)
stage (Uicc 7th)
I
II
III
IVa
IVb
IVc (metastatic)
Unknown
2 (3)
4 (5)
7 (10)
28 (38)
15 (20)
18 (24)
3
3
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vital status was available for all patients. Variables associated with 
survival were investigated using a multivariate Cox regression 
model including age, gender, stage, and PS.
PubMed literature search
The reviewed literature was identified through use of the PubMed 
search engine as of March 1, 2017. Studies were included if they 
examined the effect of hypofractionated radiotherapy (fraction 
size > 2 Gy) given with palliative intent to head and neck cancer 
patients. Studies were excluded if they primarily investigated 
radiotherapy with concurrent chemotherapy. To the extent it 
was possible, information on number of patients included in 
each study, inclusion and exclusion criteria, radiotherapy dose, 
and fractionation, along with the corresponding equivalent 
biological doses, proportion of patients with metastases, rates of 
treatment-related toxicities, OS and compliance, i.e., how many 
patients finished the intended treatment, was obtained from the 
literature. Equivalent doses in 2  Gy fractions (EQD2) for late 
effects in normal tissue were calculated for each of the regimens 
using the equation:
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2
2
, .normal Phys=
+
+
⋅
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For tumor tissue, we used a modified equation to account for 
the extended overall treatment time for the palliative regimens, 
and the equation was as follows:
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α/β ratios of 10 and 3  Gy were used for tumor tissue and late 
effects in normal tissue, respectively. DPhys was the total dose given 
in gray, d was the fraction size in gray. In calculating the EQD2 in 
tumor tissue, we used a δprolif of 0.6 Gy/day. T was overall treat-
ment time in days, and Treference was set to be the duration of our 
own regimen, i.e., 46 days. If the treatment was less than 21 days, 
we assumed there was no further benefit from the shortened 
duration, and T was set to 21 days.
Some of the quoted studies have also reported biologically 
equivalent doses, and these may differ from the doses reported 
in this paper as a result of our attempt to account for the effect of 
overall treatment time.
resUlTs
Patient characteristics
From January 2009 to December 2014, 77 patients received 
primary palliative radiotherapy with 13/14 ×  4  Gy, and were 
included in the analysis. The median age was 73  years (range 
47–96) and predominantly male (68.8%) (Table  1). The most 
common tumor sites were the oropharynx (29.9%), oral cavity 
(20.8%), larynx (18.2%), and hypopharynx (11.7%), and the most 
common histopathology was squamous cell carcinoma (93.5%). 
Of the 77 patients, 18 (23.4%) had metastatic disease from the 
outset. Forty-one (53%) patients presented with pain from tumor 
or radiating pain and 27 (35%) with dysphagia.
Fifty-eight patients (75%) completed the intended treatment 
with 13 or 14 fractions of 4 Gy. Nineteen (25%) patients discon-
tinued the treatment with a median dose of 20 Gy (range 4–40 Gy) 
delivered. The subgroup of patients that discontinued treatment 
had a worse pretreatment PS compared to the patients who com-
pleted treatment, with 47 and 10% in PS 3–4, respectively. There 
was no obvious difference in age or stage of the disease between 
these two groups.
One patient received chemotherapy before radiotherapy and 
two received chemotherapy after.
Treatment response
Two months after completed treatment, 49 (64%) patients were 
alive, of which 38 (78%) patients were evaluated for tumor res-
ponse. Twenty-four patients experienced a complete loco-regional 
response, representing 31% of the entire population, 49% of 
patients alive 2 months after treatment, and 63% of the patients 
evaluated for tumor response. Eleven patients experienced a par-
tial loco-regional response, representing 14, 22, and 29%, respec-
tively. Two patients had NC in tumor or nodal site and one patient 
experienced PD. The remaining patients were NE at the respective 
sites. Thus, a response (complete or partial) was observed in 45% 
of the entire population, 71% of patients alive at 2 months, and 
92% of patients evaluated at 2 months.
survival
The median OS for the entire population was 5.4 months, 1-year 
survival was 31% and 2-year survival was 18% (Figure 1). The 
19 patients who did not complete the intended treatment had a 
TaBle 2 | Multivariate analysis of prognostic factors for survival in patients 
receiving palliative radiotherapy.
N rr ci p Trend
age
<61 14 1 0.10
61–80 38 1.96 0.94–4.11 0.07
>80 25 1.90 0.80–4.53 0.15
gender
Male 53 1
Female 24 1.02 0.55–1.90 0.94
Ps
0–1 29 1 <0.0001
2 25 1.99 1.06–3.73 0.03
3–4 15 4.25 1.97–9.14 0.0002
Missing 8 6.77 2.14–21.41 0.001
stage
I–III 13 1
IVA 28 1.60 0.78–3.26 0.20
IVB 14 1.26 0.54–2.96 0.59
Met 18 3.63 1.49–8.86 0.005
All variables adjusted for age, gender, performance status (PS), and stage.
FigUre 1 | Kaplan–Meier survival function overall and according to presence of metastatic disease and performance status.
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median OS of 1.1 months, compared to 10.4 months survival for 
patients who completed the treatment (p < 0.001).
The median survival for WHO PS 0–2 was 5.9 months and 
for PS 3–4 1.5 months (p = 0.007). PS was not available for eight 
patients and these patients were not included in the analysis.
Using univariate analysis, PS, but not age, gender, or stage was 
significantly associated with survival. In the multivariate model 
containing the same variables, PS maintained the significance and 
metastatic disease was associated with shorter survival (Table 2).
Toxicity and late Fibrosis
The radiotherapy was generally well tolerated as seen in Table 3. 
Of the 57 patients evaluated for acute mucositis, confluent 
mucositis (grade III) was experienced in 11 (19%) patients and 
ulceration (grade IV) in 3 (5%) patients. Fifty-four patients were 
evaluated for acute dermatitis with six (11%) and two (4%) of 
these experiencing moist desquamation (grade III) and ulcera-
tion (grade IV), respectively.
Of the 49 patients surviving more than 2 months after com-
pleted treatment, 22 (45%) patients were evaluated at a later 
TaBle 3 | Highest degree of mucositis and dermatitis registered and highest 
degree of fibrosis at any time past 2 months posttreatment.
n(%)
Mucositis (n = 57)
No reaction
Erythema
Patchy mucositis
Confluent mucositis
Ulceration
4 (7)
17 (30)
22 (39)
11 (19)
3 (5)
Dermatitis (n = 54)
No reaction
Erythema
Dry desquamation
Moist desquamation
Ulceration
2 (4)
29 (54)
15 (28)
6 (11)
2 (4)
Fibrosis (n = 22)
None
Discrete fibrosis
Moderate fibrosis
Severe fibrosis
5 (23)
8 (36)
6 (27)
3 (14)
TaBle 4 | Studies reporting palliative hypofractionated radiotherapy to head–neck cancer patients (only studies with compliance data included).
reference N Total dose, gy Fx Duration, 
days
eQD2,tumor, gy eQD2,normal, gy 
(late effects)
Metastases 
(%)
Median 
overall 
survival 
(months)
acute toxicity 
grade 3/4
compliance 
(%)
Present study 77 52–56 13–14 43–46 62.5–65.3 72.8–78.4 23 5.4 Muco 24%
Derma 15%
75
Finnegan et al. (6) 70 14.8 → 44.4 (QUAD) 4 → 12 2 → 58 30.8 → 40.1 18.2 → 54.6 21 3.85 Muco 9% 76
Murthy et al. (25) 126 32 (→52) 8 (→ 13) 25 (→ 43) 49.9 (→ 62.5) 44.8 (→ 72.8) 0 5.5 Muco 0.7% 74
Lok et al. (7) 75 14.8 → 44.4 (QUAD) 4 → 12 2 → 58 30.8 → 40.1 18.2 → 54.6 55 5.67 Muco 4%
Derma 1%
37
Stevens et al. (12) 148 24–70 3–20 40 55.7a 55.0a 38 5.2 – 70
Ali et al. (21) 30 30 10 12 47.5 36.0 0 – Muco 0% 100
Pearson et al. (9) 15 14.8 → 44.4 (QUAD) 4 → 12 2 → 58 30.8 → 40.1 18.2 → 54.6 13 4 – 73
Ghoshal et al. (10) 15 14 → 28 (QUAD) 4 → 8 2 → 30 30.8 → 41.1 18.2 → 36.4 – Muco 0% 87
Agarwal et al. (26) 110 40 (→50) 16 (→ 20) 22 (→ 26) 56.1 (→ 64.1) 44.0 (→ 55.0) 0 – Derma 14%
Muco 66% 
78
Chen et al. (4) 60 QUAD; 70 Gy/35 fx; 30 Gy/10 fx; 
37.5/15 fx; 20 Gy/5 fx
– – – 100 4 Muco 15%
Derma 2% 
72
Porceddu et al. (27) 35 30 (→36) 5 (→6) 15 (→18) 55.0 (→ 63.0) 54.0 (→ 64.8) 16 6.1 Muco 26%
Derma 11%
Dysphagia 17%
88
Corry et al. (5) 30 14 → 42 (QUAD) 4 → 12 2 → 58 30.8 → 40.1 18.2 → 54.6 17 5.7 0% 53
Mohanti et al. (17) 505 20 5 5 38.8 28 0 6.6 – 100
Biswal et al. (13) 26 30 (→60) 10 (→ 25) 12 (→33) 47.5 (→ 70.3) 36.0 (→ 66.0) – 12 – 100
→, dose escalation to.
aCalculation made for regimen of 50 Gy in 16 fractions, 5 fx/week, separated by a 2-week break.
derma, dermatitis; EQD2, equivalent dose in 2 Gy fractions; Fx, fractions; Muco, mucositis; N, number of patients; QUAD, QUAD-shot.
Compliance does not include the dose escalation in parentheses, but does include the QUAD-shot dose escalation.
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follow-up for skin fibrosis of the neck. Slight fibrosis was seen as 
early as 2 months after completed treatment. The highest recorded 
degree of fibrosis seen was severe fibrosis in three patients (14%), 
moderate fibrosis in six patients (27%), slight fibrosis in eight 
patients (36%), and no fibrosis in five patients (23%).
comparable studies
We identified 23 studies that had examined hypofractionated 
palliative radiotherapy (Table 4). One study (21) was not found 
through PubMed search. Eleven were retrospective studies (4–7, 
9, 12, 14, 18, 22–24) reviewed multiple radiation therapy regimens 
(4, 11, 12, 22, 23). The studies are shown in Table 4 and the rela-
tion between the EQD2 for late effects in normal and for tumor 
tissue is shown in Figure 2. The QUAD-shot-regimen (14 Gy in 
four fractions given over two consecutive days with at least 6 h 
apart and can be repeated every four weeks) is illustrated for one, 
two, and three courses (5) (Figure 2).
DiscUssiOn
In the present study, we have examined the outcome of pal-
liative radiotherapy with 52–56 Gy in 13–14 fractions, given 
twice weekly, for head–neck cancer. Treatment response rates 
in the 38 evaluated patients were excellent with 24 patients 
having CR and 11 patients having PR, while only two and one 
had NC and PD, respectively. The regimen showed acceptable 
tolerability, in that only 14 patients (accounting for 25% of the 
patients evaluated) experienced mucositis grade 3 or more, 
and eight patients (15% of evaluated) experienced dermatitis 
grade 3 or more.
However, 25% of patients did not complete the treatment, 
mainly due to progression of disease or other circumstances such 
as dementia, poor PS, and transport issues. These patients gener-
ally had a worse PS than patients who completed the treatment 
but otherwise did not differ in age or stage. Therefore, as a result 
of the short OS and compliance of patients in poor PS (WHO 
3–4), we do not believe that the treatment regimen is suitable for 
this group of patients on a standard basis.
FigUre 2 | Relation between equivalent doses in 2-Gy fraction (EQD2) for late effects in normal tissue and tumor tissue. Data labels are “dose given, (Gy)/number of 
fractions, overall treatment time (days) (reference).” Current study has no reference and is both shown for 52 Gy in 13 fx and 56 Gy in 14 fx. QUAD-shot represented 
with doses used by Corry et al. (5). Not all studies represented in Table 4 are referenced as some studies examined the same regimen.
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Although many studies have reported outcomes of palliative 
radiotherapy in head and neck cancers, a direct comparison 
between the results is difficult. As an example Teckie et al. (22) 
only included radiotherapy with fraction doses above or equal 
to 5  Gy and examined sarcomas and melanomas in addition 
to squamous cell carcinomas, making their study population 
diverse. Furthermore, patients were excluded if they did not 
have at least one follow-up visit 30 days after end of treatment. 
Their results showed a median OS of 7.2  months and limited 
acute toxicity (1.6% grade III and IV). Nguyen et al. (18) also 
excluded patients who had no or only one follow-up after treat-
ment resulting in a median OS of 6.2  months. The exclusion 
of patients not completing the treatment or missing follow-up 
may bias results and complicate selection of the appropriate 
treatment.
The challenges comparing studies directly is also evident from 
the significant variability in how survival and morbidity are 
recorded across studies. While we used median OS measured 
from initiation of radiotherapy, other studies have used mean 
survival (15) or calculated survival from date of diagnosis (24). 
For morbidity registration, we have prospectively recoded the 
standard toxicity measures used by the Danish Head and Neck 
Cancer Group (DAHANCA) database, while other studies have 
used the RTOG/EORTC toxicity criteria.
An important aspect of palliative care that we could not exam-
ine in this study is quality of life (QoL) changes and symptom 
relief following the radiotherapy treatment. These outcomes 
have not been routinely registered in our clinic, and could not be 
reliably deducted from the medical records. However, symptom 
relief is likely to be associated with tumor response (14) and the 
combined partial and CR of 35 in 38 evaluated patients, indicates 
symptom relief in most patients.
The heterogeneity of palliative treatment schedules are illu-
strated by the significant variation in biologically equivalent 
doses to both tumor and for late effects in normal tissue. In 
our schedule, a fairly high EQD2 is delivered in the tumor tis-
sue (62.5–65.3  Gy). However, this is accompanied by a high 
EQD2 for late effects in normal tissue (72.8–78.4 Gy) which can 
explain the significant degree of moderate-severe fibrosis (>40%) 
observed in patients evaluated after 2  months. This degree of 
fibrosis may contribute to dysphagia and additional swallowing 
assessments may be relevant in long-term survivors. A slightly 
different strategy is exemplified by the schedule proposed and 
evaluated by Al-mamgani et  al. (20) (the “Christie scheme”). 
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Patients undergoing this treatment receive 50 Gy in 16 fractions, 
4–5 fractions/week (depending on the patient’s condition) result-
ing in a high EQD2 in tumor tissue (69.1 Gy, if treated with five 
fractions/week), while the corresponding EQD2 for late effects 
in normal tissue (61.3 Gy) is lower than in our study. The most 
significant difference between these two regimens is the higher 
number of fractions per week and shorter treatment duration in 
the study by Al-mamgani et al. Tissues with a high cell turnover 
like tumor and mucosa (a high α/β ratio) will be more affected by 
high EQD2,tumor doses (Figure 2) resulting in higher rates of acute 
mucositis and dermatitis. For instance, the “Christie scheme” (20) 
has one of the highest EQD2,tumor in Figure 2 and also the highest 
rates of confluent mucositis (60%) and grade III dermatitis (45%) 
reported. These proportions approach the acute side effects seen in 
curative treatment schedules and a careful selection of candidates 
for this palliative treatment may be necessary. In comparison, 
our schedule with a lower EQD2,tumor generated mucositis grade 
III and IV in 25% of patients and grade III and IV dermatitis 
in 15% of patients evaluated. In the study by Al-mamgani et al. 
patients were mostly treated with 2D technique, while all patients 
in our study received IMRT, a difference that may influence the 
presence of acute side effects as the risk of confluent mucositis is 
higher in patients treated with 2D/3D compared to IMRT (14). 
Thus, our proposed schedule may be relevant in situations where 
long-term tumor control is desired, but where the acute toxicity 
observed in other high-dose palliative schedules (14, 20) is a 
concern.
In our intention-to-treat group of patients, 25% did not com-
plete the treatment. The analysis points to PS being the most 
important factor influencing the likelihood of completing the 
treatment, and shorter treatment schedules may be better suited 
for patients in poor performance. This could have provided pal-
liation and tumor regression faster, but probably with a shorter 
overall duration. As PS may be difficult to assess, an alternative 
for patients in poor performance could be a treatment regimen 
that could be repeated or expanded based on the response and the 
constitution of the patients, such as the QUAD-shot (5).
Although the present study is retrospective in nature, patients 
were evaluated and graded prospectively. However, a limitation 
is the lack of toxicity and treatment response evaluation in all 
patients. The lack of complete toxicity evaluation may underes-
timate the acute morbidity associated with the treatment, just as 
the lack of CR evaluation may overestimate the treatment effect. 
At 2 months posttreatment, 49 patients were alive, but only 38 
(78%) evaluated. If none of the non-evaluated patients alive 
had response to treatment, the overall 2-month response rates 
(combined complete and partial) would be 71%.
The main objective of providing non-radical radiotherapy is to 
alleviate symptoms, improve QoL and achieve disease control. In 
order to select the most appropriate radiotherapy regimen and to 
compare the effects of different regimens, randomized controlled 
trials (RCTs) are much needed. We believe the hypofractionated 
regimen used in Denmark with 52–56  Gy in 13–14 fractions 
twice weekly shows good tumor response and tolerability in this 
patient population, and would be a good choice for comparison 
in an RCT. However, it may not be suited for patients in poor 
performance, but relevant for patients not suited for radical treat-
ment for other reasons (e.g., metastatic disease or comorbidity) 
when disease control is a priority.
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